Intracellular delivery of NF-κB small interfering RNA for modulating therapeutic activities of classical anti-cancer drugs in human cervical cancer cells

• DOI: 10.4081/dts.2013.e7
• Publication Date: 2013-12-10T11:55:52Z
• Authors: Anthony Stanislaus; Anil Philip Kunnath; Snigdha Tiash; Tahereh Fatemian; Nur Izyani Kamaru...; Athirah Bakhtiar; Sayyad Mustak; Sharif Hossain; Toshihiro Akaike; Ezharul Hoque Cho...
• Keywords: HeLa

Cervical cancer is the second most common and fourth leading cause of cancer-related deaths among women. Advanced stage disease treated with radiation therapy chemotherapy poor therapeutic outcome adverse side effects. NFκB, a well-known transcription factor in control immunity inflammation, has recently emerged as key regulator cell survival through induction antiapoptotic genes. Many human cancers, including cervical carcinoma, constitutively express NF-κB blockade expression its subunit proteins targeted knockdown gene transcripts small interfering RNAs (siRNA) could be an attractive approach order to sensitize cells towards widely used anti-cancer drugs. However, inefficiency naked siRNA cross plasma membrane sensitiveness nuclease-mediated degradation are major challenges limiting technology intervention. pH-sensitive carbonate apatite been established efficient nano-carrier for intracellular delivery siRNA, due strong electrostatic interaction desirable size distribution resulting complex effective endocytosis ability endocytosed released from degradable particles escape endosomes, thus target cyclin B1 or ABCB1. Here, we report that apatite-facilitated targeting NF-κB1 NF-κB2 HeLa, adenocar- cinoma line expressing NF-κB, led synergistic effect enhancement chemosensitivity doxorubicin, but apparently not cisplatin paclitaxel.